1,175 research outputs found
Senses of Self. Approaches to Pre-Reflective Self-Consciousness
No full textFrank M, Borner M, Williford KW, eds. Senses of Self. Approaches to Pre-Reflective Self-Consciousness. ProtoSociolgy. An International Journal and Interdisciplinary Project. Vol 36.; Unpublished
À propos de Thaumaloxena Wasmanni Breddin et Borner, 1904, Insecte Diptère commensal des Termites (Voyage de M. P. P. Grasse en Afrique occidentale française, 1934)
No full textPoisson Raymond A. À propos de Thaumaloxena Wasmanni Breddin et Borner, 1904, Insecte Diptère commensal des Termites (Voyage de M. P. P. Grasse en Afrique occidentale française, 1934). In: Bulletin de la Société entomologique de France, volume 42 (13-14),1937. pp. 201-208
À propos de Thaumaloxena Wasmanni Breddin et Borner, 1904, Insecte Diptère commensal des Termites (Voyage de M. P. P. Grasse en Afrique occidentale française, 1934)
No full textPoisson Raymond A. À propos de Thaumaloxena Wasmanni Breddin et Borner, 1904, Insecte Diptère commensal des Termites (Voyage de M. P. P. Grasse en Afrique occidentale française, 1934). In: Bulletin de la Société entomologique de France, volume 42 (13-14),1937. pp. 201-208
[Molecular targets in colon cancer]
No full textColorectal cancer is the second leading cause of cancer death in Switzerland. The nihilism that dominated the treatment of these patients for decades has been replaced by a measure of enthusiasm, given recent therapeutic advances. New anticancer drugs such as irinotecan and oxaliplatin have changed the standard chemotherapy treatment of metastatic colorectal cancer. However, the real hype has come from molecular targeted therapy. Identification of cellular processes characteristic of colon cancer has permitted therapeutic targeting with favorable therapeutic index. Inhibition of the epidermal growth factor receptor in the clinic has provided proof of principle that interruption of signal transduction cascades in patients has therapeutic potential. Angiogenesis, especially the vascular endothelial growth factor pathway, has been proven to be another highly successful molecular target. In this article, we will review molecular targets, which are under active clinical investigation in colon cancer
Coloradoa heinzei Borner
No full textColoradoa heinzei (Borner) (Figs. 14–20 & 22, Table 2) Lidaja heinzei Borner, 1952 Apterous viviparous female (based on 12 examined specimens): Body color green; small, 0.77–0.88 mm long; apices of antenna and SIPH, and tarsi rather dark; base of SIPH and cauda pale; dorsal hairs numerous, fanshaped; marginal tubercles absent; frons slightly convex, lateral frontal tubercles undeveloped; antenna 6 segmented, 0.53–0.63 times as long as body; secondary rhinaria absent; PT 1.44–1.76 times longer than the ANTVIb; URS pointed with concave margins, 1.24–1.40 times longer than 2 HT; first tarsal segments with 3 – 3 – 2 hairs; SIPH subcylindrical about 0.09 times as long as body, 0.78 –1.0 times as long as cauda, 0.83–0.97 times as long as URS; cauda triangular, slightly constricted at base, 0.88–1.06 times as long as URS, with 5 hairs. In this paper C. heinzei has been redescribed because Iranian specimens have some morphological differences from previously described materials by Stroyan (1979) and Heie (1992). These differences are as follows: Body length of Iranian C. heinzei is 0.77 – 0.88 mm while in the other materials it is 1.0 – 1.65 mm. The other difference is ratio between SIPH and cauda length. In Iranian samples it is between 0.78 – 1.0 times but in other materials the range is 0.58 – 0.79 times. Based on Stroyan (1979) SIPH is 0.64 – 0.91 times and Cauda 1.0– 1.3 times as long as URS, but in our specimens these ratios is between 0.83 – 0.97 and 0.88 – 1.06 times respectively. Based on Heie (1992) the antenna is 0.6–0.7 times and SIPH about 0.07 times as long as body but in Iranian specimens these are 0.53 – 0.63 and 0.09 times respectively. These morphological differences especially smaller body size in Iranian materials might be because of development on an unfavourable host or local adaptation under conditions of geographical separation. Host and distribution. Coloradoa heinzei collected on Artemisia aucheri (Asteraceae) in 6 October 2006. The species is known from one locality in Sekonge, east of Kerman Province, Iran, N 30 ° 00´23.3 ´´ E 57 ° 28´19.9 ´´, Altitude: 2474 m. TABLE 2. Biometric data of Coloradoa heinzei . Character Apterous vivipara (n= 12) Length (mm) Body 0.77–0.88 Antenna 0.45–0.49 ANTIII 0.07–0.09 ANTIV 0.05–0.06 ANTV 0.07 ANTVIb 0.07–0.08 PT 0.12–0.13 URS 0.07–0.09 2 HT 0.06 SIPH 0.07 Cauda 0.07–0.09 No. of hairs Cauda 5 No. of rhinaria ANTIII 0 ANTIV 0 ANTV 0Published as part of Mehrparvar, Mohsen & Rezwani, Ali, 2007, A new species of Macrosiphoniella and redescription of Coloradoa heinzei (Hemiptera: Sternorrhyncha: Aphididae) as a new record in Iran, pp. 61-68 in Zootaxa 1634 on pages 65-68, DOI: 10.5281/zenodo.17947
Ferric chloride/methanol in the preparation of triphenylene-based discotic liquid crystals:The synthesis of triphenylene‐based discotic mesogens New and improved routes
No full textA Commentary on the paper ''The synthesis of triphenylene-based discotic mesogens. New and improved routes'', by N. Boden, R. C. Borner, R. J. Bushby, A. N. Cammidge and M. V. Jesudason. First published in Liquid Crystals, 15, 851-858 (1993)
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial
No full textBackground: A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer.
Patients and methods: Patients with measurable unresectable and/or metastatic gastric carcinoma, World Health Organization performance status less than or equal to1, normal hematological and renal functions, adequate hepatic function and not pretreated for advanced disease by chemotherapy, received up to eight cycles of a combination of docetaxel on day 1, cisplatin on day 1 and 5-FU p.i.v. on days 1-14 (TCF) every 3 weeks, which was escalated up to the MTD, defined by the occurrence of dose-limiting toxicity in two patients in one dose level.
Results: Fifty-two patients were accrued and treated (43 in the phase I part of the trial and nine additional at the recommended dose level). A median of five cycles/patient was given. The recommended dose of TCF was docetaxel 85 mg/m(2) on day 1, cisplatin 75 mg/m(3) on day 1 and 5-FU p.i.v. 300 mg/m(2) /day on days 1-14. Grade greater than or equal to3 toxicities were neutropenia 79%, alopecia 46%, fatigue 23%, mucositis 10%, diarrhea 19%, nausea/vomiting 13%, neurological 4% and palmar-plantar 2%. Ten non-fatal febrile neutropenia episodes were recorded in eight patients. There were no treatment-related deaths. Among 41 patients with measurable disease (79%), we observed one complete and 20 partial responses for an overall intent-to-treat response rate of 51% (95% confidence interval 35-67%). Five patients (20%) had stable disease for greater than or equal to12 weeks (four cycles). The median overall survival was 9.3 months.
Conclusions: 5-FU p.i.v. at 300 mg/m(2)/day for 2 weeks out of three could be safely added to the docetaxel-cisplatin (TC) combination, but the dose of docetaxel had to be reduced to 75 mg/m(2) in a subsequent phase 11 trial. This drug regimen seems to be very active in advanced gastric cancer. Comparison with both TC and ECF in a randomized SAKK trial is ongoing
Synthesis, Structure and Magnetic Properties of Some Copper(II) Complexes Supported by Pendant Calix[4]arene Ligands
No full textThe synthesis and characterization of three new calix[4]arene ligands bearing two pendant acylhydrazone arms and some of their Cu2+ complexes, namely [Cu(L1-2H)(MeOH)] (3), [Cu(L1’-H)(Cl)(2-hydroxy-1-naphthaldehyde)] (4), [Cu2(L2-2H)2] (5) and [Cu4(L3-2H)2(OH)2(ClO4)2] (6) are described. The ligands are obtained by simple imine condensation reactions between calix[4]arene-1,3-bis-acyl-hydrazides and the corresponding carbaldehydes. The Cu2+ ions are always situated in 5-membered chelate rings, either in a deprotonated −O−CR=N−N=CHR (enolate) or a neutral O=CR−NH−N=CHR (keto) form. In 3 and 4 a 5-membered chelate ring is formed through interaction of the Cu2+ ion with the naphtholato group. Additional MeOH, chlorido or naphthaldehyde ligands complete the planar (3) or square pyramidal (4) coordination spheres. The thiophenes in 5 do not interact with the Cu2+ ions and dimerization of [CuL] entities occurs to produce centrosymmetric 2 : 2 complexes with four-coordinated Cu2+ ions. In 6, two dinuclear [Cu2(L3-2H)(OH)] subunits are connected by μ1,3-bridging ClO4− ions. The magnetic properties of polycrystalline samples of 5 and 6 were studied by variable temperature magnetic susceptibility measurements. The χ′′(T) vs T plots indicate antiferromagnetic exchange interactions. The exchange interactions in 6 (J=−4.8 cm−1) were found to be stronger than in 5 (J=−0.54 cm−1). This is also supported by broken symmetry DFT calculations
Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true?
No full textIrinotecan in combination with new agents
No full textToday, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with novel, targeted agents has been investigated. The theoretical attraction of combining irinotecan with targeted therapies is that this can improve the efficacy of treatment, but, due to the mainly non-overlapping toxicities of the agents involved, the toxicity of treatment should not be exacerbated. In this article we discuss recent data from clinical studies looking at the combinations of irinotecan with the 5-fluorouracil (5-FU) pro-drug, capecitabine, the cyclo-oxygenase (COX-2) inhibitor, celecoxib, and monoclonal antibodies against the epidermal growth factor receptor (cetuximab) and vascular endothelial growth factor (bevacizumab). © 2004 Elsevier Ltd. All rights reserved.SCOPUS: re.jinfo:eu-repo/semantics/publishe
- …
